ARS Pharmaceuticals, Inc. (SPRY)

NasdaqGM · Biotechnology

5.87
-0.14 (-2.25%)
Updated Sep 1, 7:01 PM ET
AI Rating
Sell
Overall Score
31
Trend
0
Momentum
70
Risk
24

Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.

Price history

Daily closes and volume
Aug 18, 2025 260 sessions Aug 28, 2026

AI Analysis

ARS Pharmaceuticals, Inc. is trading at $5.87, down 2.25% on the session. The 50 day average sits at $6.86 and the 200 day at $8.63, which puts the stock in a downtrend. RSI is at 46.5, which reads as neutral, and MACD is bullish crossover. Volume is below average.

The nearest support is around $5.20 with resistance near $6.58, so that band frames the current range. Average daily movement is roughly $0.42, or about 7.2% of the share price, which is what any stop placement has to allow for. The overall health score of 31 out of 100 combines a trend score of 0, momentum of 70 and a risk score of 24.

Technical indicators

RSI (14)
46.5
neutral
MACD
-0.216
bullish crossover
SMA 20
5.82
SMA 50
6.86
SMA 200
8.63
downtrend
ATR (14)
0.42
avg daily range
Support
5.20
Resistance
6.58
Volume vs 20d
0.62x
below average
Volatility
92.3%
annualised
1 month
+4.62%
3 months
-35.06%

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Company website

Stay Ahead of the Market

Get daily AI insights, market updates, and trade opportunities delivered to your inbox.